Higher Bleeding Risk Seen With Rivaroxaban Versus Dabigatran

This article originally appeared here.
Share this content:
Higher Bleeding Risk Seen With Rivaroxaban Versus Dabigatran
Higher Bleeding Risk Seen With Rivaroxaban Versus Dabigatran

MONDAY, Oct. 3, 2016 (HealthDay News) -- Rivaroxaban may pose a slightly greater risk of serious bleeding than dabigatran in patients with atrial fibrillation, according to a study published online Oct. 3 in JAMA Internal Medicine.

David Graham, M.D., M.P.H., associate director of science at the U.S. Food and Drug Administration's Center for Drug Evaluation and Research, and colleagues collected data on 118,891 Medicare patients with atrial fibrillation treated with either rivaroxaban or dabigatran from November 2011 through June 2014.

The team found little difference in stroke risk among patients taking either dabigatran or rivaroxaban. But, there was a small yet statistically significant increase in risk of intracranial hemorrhage and major gastrointestinal bleeding in patients taking rivaroxaban (hazard ratios, 1.65 and 1.40, respectively). And among certain patients 75 and older, rivaroxaban was associated with a small but statistically significant increased risk of death.

"In this large direct comparison of patients with atrial fibrillation treated with dabigatran or rivaroxaban, rivaroxaban use was associated with statistically significant increases in the risk of intracranial hemorrhage and major extracranial bleeding, including major gastrointestinal bleeding, and possibly with increased mortality in older patients or those with higher baseline risk of stroke," the authors write. "The greater anticoagulant effect observed with rivaroxaban treatment may be due to the higher dose required for once-daily dosing. A contribution to this effect by off-label use of standard-dose rivaroxaban in patients with impaired renal function cannot be excluded."

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Gene Tx Approved for Certain Types of B-Cell Lymphoma

Gene Tx Approved for Certain Types of B-Cell ...

First such treatment for certain types of non-Hodgkin lymphoma

Uninsurance Down by One-Third for Cancer Diagnoses in 2014

Uninsurance Down by One-Third for Cancer Diagnoses in ...

Significant decreases in uninsurance seen across all stages and sites assessed in first year of ACA

Diabetes Ups Risk of MACE in Acute Coronary Syndromes

Diabetes Ups Risk of MACE in Acute Coronary ...

Diabetes, but not pre-diabetes, tied to increased risk of major adverse cardiac events in adjusted model

is free, fast, and customized just for you!

Already a member?

Sign In Now »